Neramexane (merz pharmaceuticals/forest laboratories).
Article Details
- CitationCopy to clipboard
Rammes G, Schierloh A
Neramexane (merz pharmaceuticals/forest laboratories).
IDrugs. 2006 Feb;9(2):128-35.
- PubMed ID
- 16523403 [ View in PubMed]
- Abstract
Merz Pharmaceuticals GmbH and Forest Laboratories Inc are developing neramexane, an oral N-methyl-D-aspartate antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.
DrugBank Data that Cites this Article
- Drugs